Get started
Author

Gero Joks

Observed name: G. Joks
Observed institution: Janssen Australia (Australia)
ORCID: 0000-0002-4484-8578
Observed ORCID: 0000-0002-4484-8578
OpenAlex ID: A5093210072
A real-world study examining the impact of esketamine nasal spray in people living with major depressive disorder in Australia and New Zealand
2024 · Malcolm Hopwood, Elizabeth M. Scott, et al. · Psychiatry Research Communications · 9
Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G‐EPOSS study
2024 · S. Gerdes, R. Ostendorf, et al. · Journal of the European Academy of Dermatology and Venereology · 8
PDF
Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel
2023 · Nicollette L. R. Thornton, Warwick Black, et al. · Asia-Pacific Psychiatry · 5
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al
2024 · Gero Joks, Steve Su, et al. · The British Journal of Psychiatry
PDF
26573 Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
2021 · Curdin Conrad, Andreas Körber, et al. · Journal of the American Academy of Dermatology
Works count: 5
Citation count: 22
H-index: 3
I10-index:
Year
Topic
Type